For decades, chronic kidney disease has been a difficult condition to treat. Once kidney function begins to decline, doctors can often slow the damage but rarely stop it completely.
Millions of patients eventually face dialysis, kidney transplantation, serious heart complications, or early death. New research now suggests that an existing medicine called finerenone may offer important protection for far more patients than previously recognized.
The findings come from a collection of major international studies led by researchers from The George Institute for Global Health.
The results were presented at a major kidney conference in the United Kingdom and published simultaneously in The Lancet, The New England Journal of Medicine, and JAMA. Such coordinated publication is rare and usually reflects research that could significantly influence medical practice.
Chronic kidney disease affects about one in ten people worldwide. The kidneys play a vital role by filtering waste products, balancing fluids, and helping regulate blood pressure. When they become damaged, these functions gradually weaken. Many people with kidney disease also face a much higher risk of heart attacks, heart failure, and stroke.
Finerenone belongs to a class of medicines that block harmful activity involving the mineralocorticoid receptor. Excess activity of this receptor can cause inflammation and scarring throughout the kidneys.
Scientists believed that blocking this process could slow disease progression, but until recently the drug was mainly recommended for patients who had both chronic kidney disease and type 2 diabetes.
Researchers wanted to know whether the benefits might extend to people without diabetes. Their first study followed 1,584 patients with non-diabetic chronic kidney disease from 24 countries.
The results showed that patients taking finerenone experienced slower kidney function decline and a substantially lower risk of serious kidney and cardiovascular complications.
A second study focused on people with glomerular diseases. These illnesses damage the tiny filtering structures inside the kidneys and can eventually lead to kidney failure. Patients in this group often have limited treatment choices.
Finerenone reduced disease progression and significantly lowered levels of protein in the urine, which is considered an important sign of kidney injury.
The third study combined information from several large trials involving more than 14,500 patients. This pooled analysis provided a broader picture of the drug’s effects across different types of kidney disease.
Researchers found that finerenone reduced the risk of kidney failure or worsening kidney disease by nearly one quarter. It also reduced hospitalizations for heart failure and deaths related to cardiovascular disease. Importantly, the drug was associated with a reduction in deaths from all causes.
These findings matter because kidney disease and heart disease are closely connected. Many patients with chronic kidney disease die from cardiovascular complications before ever reaching kidney failure. A treatment that protects both organs could therefore provide substantial health benefits.
The safety findings were also reassuring. Although elevated potassium levels occurred more frequently among patients receiving finerenone, serious complications remained uncommon. Most patients were able to continue treatment without major problems.
Researchers say the results could change how doctors think about chronic kidney disease. Rather than reserving finerenone mainly for patients with diabetes, future guidelines may expand its use to include many patients with non-diabetic kidney disease as well.
There are still questions that future studies will need to answer. Researchers will continue monitoring long-term outcomes and determining which patient groups benefit the most. Cost, access, and practical monitoring requirements will also influence how widely the treatment is adopted.
Even so, the evidence is impressive. The studies involved large patient populations, used rigorous clinical trial methods, and produced consistent findings across multiple analyses. This makes the conclusions more reliable than those from a single study alone.
If you care about kidney health, please read studies about how to protect your kidneys from diabetes, and drinking coffee could help reduce risk of kidney injury.
For more health information, please see recent studies about foods that may prevent recurrence of kidney stones, and eating nuts linked to lower risk of chronic kidney disease and death.
Source: The George Institute for Global Health.
